nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Cladribine—multiple sclerosis	0.57	1	CrCtD
Vidarabine—Pentostatin—Cladribine—multiple sclerosis	0.0565	0.151	CrCrCtD
Vidarabine—Regadenoson—Cladribine—multiple sclerosis	0.0449	0.12	CrCrCtD
Vidarabine—Clofarabine—Cladribine—multiple sclerosis	0.0449	0.12	CrCrCtD
Vidarabine—Fludarabine—Cladribine—multiple sclerosis	0.0421	0.113	CrCrCtD
Vidarabine—Adenosine monophosphate—Cladribine—multiple sclerosis	0.0397	0.106	CrCrCtD
Vidarabine—Nelarabine—Cladribine—multiple sclerosis	0.0397	0.106	CrCrCtD
Vidarabine—Azacitidine—Cladribine—multiple sclerosis	0.0356	0.0956	CrCrCtD
Vidarabine—Adenosine—Cladribine—multiple sclerosis	0.0356	0.0956	CrCrCtD
Vidarabine—Decitabine—Cladribine—multiple sclerosis	0.034	0.0911	CrCrCtD
Vidarabine—S-Adenosylmethionine—SRM—multiple sclerosis	0.00121	0.367	CrCbGaD
Vidarabine—Clofarabine—RRM1—multiple sclerosis	0.000519	0.157	CrCbGaD
Vidarabine—Fludarabine—RRM1—multiple sclerosis	0.000503	0.152	CrCbGaD
Vidarabine—ADK—retina—multiple sclerosis	0.00043	0.0893	CbGeAlD
Vidarabine—Glucosamine—IFNG—multiple sclerosis	0.000376	0.114	CrCbGaD
Vidarabine—ADK—medulla oblongata—multiple sclerosis	0.000311	0.0645	CbGeAlD
Vidarabine—ADORA2A—spinal cord—multiple sclerosis	0.000308	0.0641	CbGeAlD
Vidarabine—Cladribine—RRM1—multiple sclerosis	0.000298	0.0902	CrCbGaD
Vidarabine—ADA—nervous system—multiple sclerosis	0.000286	0.0593	CbGeAlD
Vidarabine—ADK—midbrain—multiple sclerosis	0.000284	0.059	CbGeAlD
Vidarabine—ADK—spinal cord—multiple sclerosis	0.000277	0.0575	CbGeAlD
Vidarabine—ADA—central nervous system—multiple sclerosis	0.000275	0.0571	CbGeAlD
Vidarabine—ADK—Nucleotide metabolism—RRM1—multiple sclerosis	0.000263	0.0688	CbGpPWpGaD
Vidarabine—ADORA2A—nervous system—multiple sclerosis	0.00026	0.054	CbGeAlD
Vidarabine—ADORA2A—central nervous system—multiple sclerosis	0.00025	0.052	CbGeAlD
Vidarabine—ADORA2A—cerebellum—multiple sclerosis	0.000244	0.0508	CbGeAlD
Vidarabine—Glucosamine—MMP9—multiple sclerosis	0.00024	0.0725	CrCbGaD
Vidarabine—ADK—nervous system—multiple sclerosis	0.000233	0.0485	CbGeAlD
Vidarabine—DPP4—nervous system—multiple sclerosis	0.000226	0.047	CbGeAlD
Vidarabine—ADK—central nervous system—multiple sclerosis	0.000225	0.0467	CbGeAlD
Vidarabine—ADK—cerebellum—multiple sclerosis	0.00022	0.0456	CbGeAlD
Vidarabine—ADA—brain—multiple sclerosis	0.000218	0.0454	CbGeAlD
Vidarabine—DPP4—central nervous system—multiple sclerosis	0.000218	0.0453	CbGeAlD
Vidarabine—DPP4—Peptide hormone metabolism—SLC30A7—multiple sclerosis	0.000215	0.0563	CbGpPWpGaD
Vidarabine—ADORA2A—brain—multiple sclerosis	0.000199	0.0413	CbGeAlD
Vidarabine—ADA—p73 transcription factor network—IL4R—multiple sclerosis	0.00019	0.0498	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—RRM1—multiple sclerosis	0.000179	0.0468	CbGpPWpGaD
Vidarabine—ADK—brain—multiple sclerosis	0.000178	0.0371	CbGeAlD
Vidarabine—DPP4—brain—multiple sclerosis	0.000173	0.0359	CbGeAlD
Vidarabine—Glucosamine—TNF—multiple sclerosis	0.000158	0.0476	CrCbGaD
Vidarabine—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.000121	0.00271	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisolone—multiple sclerosis	0.000121	0.00269	CcSEcCtD
Vidarabine—Arrhythmia—Mitoxantrone—multiple sclerosis	0.00012	0.00269	CcSEcCtD
Vidarabine—Cardiac failure—Prednisone—multiple sclerosis	0.000119	0.00266	CcSEcCtD
Vidarabine—Urticaria—Cladribine—multiple sclerosis	0.000116	0.00258	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—VDR—multiple sclerosis	0.000116	0.0303	CbGpPWpGaD
Vidarabine—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000115	0.00256	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—BCHE—multiple sclerosis	0.000115	0.0301	CbGpPWpGaD
Vidarabine—Affect lability—Prednisone—multiple sclerosis	0.000114	0.00255	CcSEcCtD
Vidarabine—Back pain—Mitoxantrone—multiple sclerosis	0.000114	0.00253	CcSEcCtD
Vidarabine—Bradycardia—Prednisolone—multiple sclerosis	0.000113	0.00251	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—S1PR1—multiple sclerosis	0.000113	0.0294	CbGpPWpGaD
Vidarabine—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.000112	0.00249	CcSEcCtD
Vidarabine—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.000111	0.00249	CcSEcCtD
Vidarabine—Myocardial infarction—Triamcinolone—multiple sclerosis	0.000111	0.00248	CcSEcCtD
Vidarabine—Myocardial infarction—Methylprednisolone—multiple sclerosis	0.000111	0.00247	CcSEcCtD
Vidarabine—Hypotension—Azathioprine—multiple sclerosis	0.000111	0.00247	CcSEcCtD
Vidarabine—Vision blurred—Mitoxantrone—multiple sclerosis	0.000111	0.00247	CcSEcCtD
Vidarabine—Cardiac arrest—Prednisone—multiple sclerosis	0.00011	0.00246	CcSEcCtD
Vidarabine—Mood swings—Prednisone—multiple sclerosis	0.00011	0.00246	CcSEcCtD
Vidarabine—Sweating—Methylprednisolone—multiple sclerosis	0.000108	0.00242	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000108	0.00241	CcSEcCtD
Vidarabine—Hypersensitivity—Cladribine—multiple sclerosis	0.000107	0.0024	CcSEcCtD
Vidarabine—Asthenia—Cladribine—multiple sclerosis	0.000105	0.00233	CcSEcCtD
Vidarabine—Bradycardia—Triamcinolone—multiple sclerosis	0.000104	0.00231	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—VDR—multiple sclerosis	0.000104	0.0271	CbGpPWpGaD
Vidarabine—Bradycardia—Methylprednisolone—multiple sclerosis	0.000103	0.0023	CcSEcCtD
Vidarabine—Cough—Mitoxantrone—multiple sclerosis	0.000102	0.00228	CcSEcCtD
Vidarabine—Convulsion—Mitoxantrone—multiple sclerosis	0.000102	0.00227	CcSEcCtD
Vidarabine—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.000101	0.00226	CcSEcCtD
Vidarabine—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.000101	0.00226	CcSEcCtD
Vidarabine—Hypertension—Mitoxantrone—multiple sclerosis	0.000101	0.00226	CcSEcCtD
Vidarabine—Myocardial infarction—Betamethasone—multiple sclerosis	0.000101	0.00225	CcSEcCtD
Vidarabine—Myocardial infarction—Dexamethasone—multiple sclerosis	0.000101	0.00225	CcSEcCtD
Vidarabine—Chest pain—Mitoxantrone—multiple sclerosis	9.99e-05	0.00223	CcSEcCtD
Vidarabine—Anxiety—Mitoxantrone—multiple sclerosis	9.96e-05	0.00222	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—multiple sclerosis	9.91e-05	0.00221	CcSEcCtD
Vidarabine—Arrhythmia—Prednisolone—multiple sclerosis	9.88e-05	0.0022	CcSEcCtD
Vidarabine—Discomfort—Mitoxantrone—multiple sclerosis	9.87e-05	0.0022	CcSEcCtD
Vidarabine—Dizziness—Cladribine—multiple sclerosis	9.64e-05	0.00215	CcSEcCtD
Vidarabine—Anaphylactic shock—Mitoxantrone—multiple sclerosis	9.58e-05	0.00214	CcSEcCtD
Vidarabine—Shock—Mitoxantrone—multiple sclerosis	9.42e-05	0.0021	CcSEcCtD
Vidarabine—Cardiac disorder—Methylprednisolone—multiple sclerosis	9.42e-05	0.0021	CcSEcCtD
Vidarabine—Bradycardia—Dexamethasone—multiple sclerosis	9.39e-05	0.0021	CcSEcCtD
Vidarabine—Bradycardia—Betamethasone—multiple sclerosis	9.39e-05	0.0021	CcSEcCtD
Vidarabine—Tachycardia—Mitoxantrone—multiple sclerosis	9.35e-05	0.00209	CcSEcCtD
Vidarabine—Vomiting—Cladribine—multiple sclerosis	9.26e-05	0.00207	CcSEcCtD
Vidarabine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	9.26e-05	0.00207	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—multiple sclerosis	9.2e-05	0.00205	CcSEcCtD
Vidarabine—Rash—Cladribine—multiple sclerosis	9.19e-05	0.00205	CcSEcCtD
Vidarabine—Dermatitis—Cladribine—multiple sclerosis	9.18e-05	0.00205	CcSEcCtD
Vidarabine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	9.15e-05	0.00204	CcSEcCtD
Vidarabine—Headache—Cladribine—multiple sclerosis	9.13e-05	0.00204	CcSEcCtD
Vidarabine—Arrhythmia—Triamcinolone—multiple sclerosis	9.09e-05	0.00203	CcSEcCtD
Vidarabine—Vision blurred—Prednisolone—multiple sclerosis	9.07e-05	0.00202	CcSEcCtD
Vidarabine—Arrhythmia—Methylprednisolone—multiple sclerosis	9.07e-05	0.00202	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—FAS—multiple sclerosis	9.03e-05	0.0236	CbGpPWpGaD
Vidarabine—Hypotension—Mitoxantrone—multiple sclerosis	8.95e-05	0.002	CcSEcCtD
Vidarabine—Acute coronary syndrome—Prednisone—multiple sclerosis	8.83e-05	0.00197	CcSEcCtD
Vidarabine—Angioedema—Prednisolone—multiple sclerosis	8.8e-05	0.00196	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisone—multiple sclerosis	8.78e-05	0.00196	CcSEcCtD
Vidarabine—Hypersensitivity—Azathioprine—multiple sclerosis	8.73e-05	0.00195	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	8.73e-05	0.00195	CcSEcCtD
Vidarabine—Dysgeusia—Triamcinolone—multiple sclerosis	8.67e-05	0.00193	CcSEcCtD
Vidarabine—Nausea—Cladribine—multiple sclerosis	8.65e-05	0.00193	CcSEcCtD
Vidarabine—Syncope—Prednisolone—multiple sclerosis	8.63e-05	0.00193	CcSEcCtD
Vidarabine—Paraesthesia—Mitoxantrone—multiple sclerosis	8.6e-05	0.00192	CcSEcCtD
Vidarabine—Back pain—Triamcinolone—multiple sclerosis	8.56e-05	0.00191	CcSEcCtD
Vidarabine—Dyspnoea—Mitoxantrone—multiple sclerosis	8.54e-05	0.00191	CcSEcCtD
Vidarabine—Somnolence—Mitoxantrone—multiple sclerosis	8.51e-05	0.0019	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisolone—multiple sclerosis	8.46e-05	0.00189	CcSEcCtD
Vidarabine—Convulsion—Prednisolone—multiple sclerosis	8.34e-05	0.00186	CcSEcCtD
Vidarabine—Hypertension—Prednisolone—multiple sclerosis	8.31e-05	0.00185	CcSEcCtD
Vidarabine—Arrhythmia—Dexamethasone—multiple sclerosis	8.24e-05	0.00184	CcSEcCtD
Vidarabine—Arrhythmia—Betamethasone—multiple sclerosis	8.24e-05	0.00184	CcSEcCtD
Vidarabine—Pain—Mitoxantrone—multiple sclerosis	8.19e-05	0.00183	CcSEcCtD
Vidarabine—Bradycardia—Prednisone—multiple sclerosis	8.18e-05	0.00183	CcSEcCtD
Vidarabine—Discomfort—Prednisolone—multiple sclerosis	8.1e-05	0.00181	CcSEcCtD
Vidarabine—Angioedema—Triamcinolone—multiple sclerosis	8.09e-05	0.0018	CcSEcCtD
Vidarabine—Angioedema—Methylprednisolone—multiple sclerosis	8.07e-05	0.0018	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—multiple sclerosis	8.04e-05	0.00179	CcSEcCtD
Vidarabine—Syncope—Triamcinolone—multiple sclerosis	7.94e-05	0.00177	CcSEcCtD
Vidarabine—Syncope—Methylprednisolone—multiple sclerosis	7.92e-05	0.00177	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisolone—multiple sclerosis	7.86e-05	0.00175	CcSEcCtD
Vidarabine—Dizziness—Azathioprine—multiple sclerosis	7.83e-05	0.00175	CcSEcCtD
Vidarabine—Loss of consciousness—Triamcinolone—multiple sclerosis	7.78e-05	0.00174	CcSEcCtD
Vidarabine—Loss of consciousness—Methylprednisolone—multiple sclerosis	7.76e-05	0.00173	CcSEcCtD
Vidarabine—Shock—Prednisolone—multiple sclerosis	7.73e-05	0.00172	CcSEcCtD
Vidarabine—Cough—Triamcinolone—multiple sclerosis	7.73e-05	0.00172	CcSEcCtD
Vidarabine—Convulsion—Triamcinolone—multiple sclerosis	7.67e-05	0.00171	CcSEcCtD
Vidarabine—Tachycardia—Prednisolone—multiple sclerosis	7.67e-05	0.00171	CcSEcCtD
Vidarabine—Convulsion—Methylprednisolone—multiple sclerosis	7.65e-05	0.00171	CcSEcCtD
Vidarabine—Hypertension—Triamcinolone—multiple sclerosis	7.64e-05	0.00171	CcSEcCtD
Vidarabine—Hypertension—Methylprednisolone—multiple sclerosis	7.63e-05	0.0017	CcSEcCtD
Vidarabine—Urticaria—Mitoxantrone—multiple sclerosis	7.61e-05	0.0017	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisolone—multiple sclerosis	7.6e-05	0.00169	CcSEcCtD
Vidarabine—Vomiting—Azathioprine—multiple sclerosis	7.53e-05	0.00168	CcSEcCtD
Vidarabine—Anxiety—Methylprednisolone—multiple sclerosis	7.49e-05	0.00167	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—multiple sclerosis	7.48e-05	0.00167	CcSEcCtD
Vidarabine—Rash—Azathioprine—multiple sclerosis	7.47e-05	0.00167	CcSEcCtD
Vidarabine—Dermatitis—Azathioprine—multiple sclerosis	7.46e-05	0.00167	CcSEcCtD
Vidarabine—Flushing—Prednisone—multiple sclerosis	7.46e-05	0.00166	CcSEcCtD
Vidarabine—Discomfort—Triamcinolone—multiple sclerosis	7.45e-05	0.00166	CcSEcCtD
Vidarabine—Discomfort—Methylprednisolone—multiple sclerosis	7.43e-05	0.00166	CcSEcCtD
Vidarabine—Headache—Azathioprine—multiple sclerosis	7.42e-05	0.00166	CcSEcCtD
Vidarabine—Dry mouth—Triamcinolone—multiple sclerosis	7.37e-05	0.00164	CcSEcCtD
Vidarabine—Angioedema—Betamethasone—multiple sclerosis	7.34e-05	0.00164	CcSEcCtD
Vidarabine—Angioedema—Dexamethasone—multiple sclerosis	7.34e-05	0.00164	CcSEcCtD
Vidarabine—Anaphylactic shock—Triamcinolone—multiple sclerosis	7.23e-05	0.00161	CcSEcCtD
Vidarabine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	7.21e-05	0.00161	CcSEcCtD
Vidarabine—Syncope—Betamethasone—multiple sclerosis	7.2e-05	0.00161	CcSEcCtD
Vidarabine—Syncope—Dexamethasone—multiple sclerosis	7.2e-05	0.00161	CcSEcCtD
Vidarabine—Arrhythmia—Prednisone—multiple sclerosis	7.18e-05	0.0016	CcSEcCtD
Vidarabine—Sweating—Methotrexate—multiple sclerosis	7.17e-05	0.0016	CcSEcCtD
Vidarabine—Shock—Triamcinolone—multiple sclerosis	7.11e-05	0.00159	CcSEcCtD
Vidarabine—Shock—Methylprednisolone—multiple sclerosis	7.09e-05	0.00158	CcSEcCtD
Vidarabine—Loss of consciousness—Dexamethasone—multiple sclerosis	7.06e-05	0.00158	CcSEcCtD
Vidarabine—Loss of consciousness—Betamethasone—multiple sclerosis	7.06e-05	0.00158	CcSEcCtD
Vidarabine—Hypersensitivity—Mitoxantrone—multiple sclerosis	7.06e-05	0.00157	CcSEcCtD
Vidarabine—Paraesthesia—Prednisolone—multiple sclerosis	7.06e-05	0.00157	CcSEcCtD
Vidarabine—Tachycardia—Triamcinolone—multiple sclerosis	7.05e-05	0.00157	CcSEcCtD
Vidarabine—Nausea—Azathioprine—multiple sclerosis	7.04e-05	0.00157	CcSEcCtD
Vidarabine—Tachycardia—Methylprednisolone—multiple sclerosis	7.04e-05	0.00157	CcSEcCtD
Vidarabine—Hyperhidrosis—Triamcinolone—multiple sclerosis	6.99e-05	0.00156	CcSEcCtD
Vidarabine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	6.97e-05	0.00155	CcSEcCtD
Vidarabine—Convulsion—Betamethasone—multiple sclerosis	6.96e-05	0.00155	CcSEcCtD
Vidarabine—Convulsion—Dexamethasone—multiple sclerosis	6.96e-05	0.00155	CcSEcCtD
Vidarabine—Hypertension—Betamethasone—multiple sclerosis	6.94e-05	0.00155	CcSEcCtD
Vidarabine—Hypertension—Dexamethasone—multiple sclerosis	6.94e-05	0.00155	CcSEcCtD
Vidarabine—Asthenia—Mitoxantrone—multiple sclerosis	6.87e-05	0.00153	CcSEcCtD
Vidarabine—Anxiety—Dexamethasone—multiple sclerosis	6.82e-05	0.00152	CcSEcCtD
Vidarabine—Anxiety—Betamethasone—multiple sclerosis	6.82e-05	0.00152	CcSEcCtD
Vidarabine—Discomfort—Betamethasone—multiple sclerosis	6.76e-05	0.00151	CcSEcCtD
Vidarabine—Discomfort—Dexamethasone—multiple sclerosis	6.76e-05	0.00151	CcSEcCtD
Vidarabine—Hypotension—Methylprednisolone—multiple sclerosis	6.74e-05	0.0015	CcSEcCtD
Vidarabine—Pain—Prednisolone—multiple sclerosis	6.72e-05	0.0015	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—FAS—multiple sclerosis	6.66e-05	0.0174	CbGpPWpGaD
Vidarabine—Vision blurred—Prednisone—multiple sclerosis	6.59e-05	0.00147	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	6.58e-05	0.00147	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	6.57e-05	0.00147	CcSEcCtD
Vidarabine—Anaphylactic shock—Dexamethasone—multiple sclerosis	6.56e-05	0.00146	CcSEcCtD
Vidarabine—Anaphylactic shock—Betamethasone—multiple sclerosis	6.56e-05	0.00146	CcSEcCtD
Vidarabine—Paraesthesia—Triamcinolone—multiple sclerosis	6.49e-05	0.00145	CcSEcCtD
Vidarabine—Paraesthesia—Methylprednisolone—multiple sclerosis	6.47e-05	0.00144	CcSEcCtD
Vidarabine—Shock—Dexamethasone—multiple sclerosis	6.45e-05	0.00144	CcSEcCtD
Vidarabine—Shock—Betamethasone—multiple sclerosis	6.45e-05	0.00144	CcSEcCtD
Vidarabine—Dyspnoea—Triamcinolone—multiple sclerosis	6.44e-05	0.00144	CcSEcCtD
Vidarabine—Agitation—Prednisone—multiple sclerosis	6.43e-05	0.00143	CcSEcCtD
Vidarabine—Tachycardia—Dexamethasone—multiple sclerosis	6.4e-05	0.00143	CcSEcCtD
Vidarabine—Tachycardia—Betamethasone—multiple sclerosis	6.4e-05	0.00143	CcSEcCtD
Vidarabine—Angioedema—Prednisone—multiple sclerosis	6.39e-05	0.00143	CcSEcCtD
Vidarabine—Hyperhidrosis—Dexamethasone—multiple sclerosis	6.34e-05	0.00141	CcSEcCtD
Vidarabine—Hyperhidrosis—Betamethasone—multiple sclerosis	6.34e-05	0.00141	CcSEcCtD
Vidarabine—Syncope—Prednisone—multiple sclerosis	6.27e-05	0.0014	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—multiple sclerosis	6.26e-05	0.0014	CcSEcCtD
Vidarabine—Urticaria—Prednisolone—multiple sclerosis	6.24e-05	0.00139	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—multiple sclerosis	6.23e-05	0.00139	CcSEcCtD
Vidarabine—Pain—Triamcinolone—multiple sclerosis	6.18e-05	0.00138	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisone—multiple sclerosis	6.15e-05	0.00137	CcSEcCtD
Vidarabine—Hypotension—Betamethasone—multiple sclerosis	6.13e-05	0.00137	CcSEcCtD
Vidarabine—Hypotension—Dexamethasone—multiple sclerosis	6.13e-05	0.00137	CcSEcCtD
Vidarabine—Vomiting—Mitoxantrone—multiple sclerosis	6.09e-05	0.00136	CcSEcCtD
Vidarabine—Convulsion—Prednisone—multiple sclerosis	6.06e-05	0.00135	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—multiple sclerosis	6.05e-05	0.00135	CcSEcCtD
Vidarabine—Hypertension—Prednisone—multiple sclerosis	6.04e-05	0.00135	CcSEcCtD
Vidarabine—Rash—Mitoxantrone—multiple sclerosis	6.04e-05	0.00135	CcSEcCtD
Vidarabine—Dermatitis—Mitoxantrone—multiple sclerosis	6.03e-05	0.00135	CcSEcCtD
Vidarabine—Headache—Mitoxantrone—multiple sclerosis	6e-05	0.00134	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	5.97e-05	0.00133	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	5.97e-05	0.00133	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—LINGO1—multiple sclerosis	5.94e-05	0.0155	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—POMC—multiple sclerosis	5.94e-05	0.0155	CbGpPWpGaD
Vidarabine—Anxiety—Prednisone—multiple sclerosis	5.94e-05	0.00132	CcSEcCtD
Vidarabine—Paraesthesia—Dexamethasone—multiple sclerosis	5.89e-05	0.00131	CcSEcCtD
Vidarabine—Paraesthesia—Betamethasone—multiple sclerosis	5.89e-05	0.00131	CcSEcCtD
Vidarabine—Discomfort—Prednisone—multiple sclerosis	5.88e-05	0.00131	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisolone—multiple sclerosis	5.79e-05	0.00129	CcSEcCtD
Vidarabine—Urticaria—Triamcinolone—multiple sclerosis	5.74e-05	0.00128	CcSEcCtD
Vidarabine—Urticaria—Methylprednisolone—multiple sclerosis	5.73e-05	0.00128	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—multiple sclerosis	5.73e-05	0.00128	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisone—multiple sclerosis	5.71e-05	0.00127	CcSEcCtD
Vidarabine—Nausea—Mitoxantrone—multiple sclerosis	5.69e-05	0.00127	CcSEcCtD
Vidarabine—Back pain—Methotrexate—multiple sclerosis	5.66e-05	0.00126	CcSEcCtD
Vidarabine—Shock—Prednisone—multiple sclerosis	5.62e-05	0.00125	CcSEcCtD
Vidarabine—Pain—Dexamethasone—multiple sclerosis	5.61e-05	0.00125	CcSEcCtD
Vidarabine—Pain—Betamethasone—multiple sclerosis	5.61e-05	0.00125	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—multiple sclerosis	5.57e-05	0.00124	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—multiple sclerosis	5.52e-05	0.00123	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—multiple sclerosis	5.51e-05	0.00123	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—CXCR3—multiple sclerosis	5.5e-05	0.0144	CbGpPWpGaD
Vidarabine—Hypersensitivity—Triamcinolone—multiple sclerosis	5.32e-05	0.00119	CcSEcCtD
Vidarabine—Hypersensitivity—Methylprednisolone—multiple sclerosis	5.31e-05	0.00119	CcSEcCtD
Vidarabine—Urticaria—Betamethasone—multiple sclerosis	5.21e-05	0.00116	CcSEcCtD
Vidarabine—Urticaria—Dexamethasone—multiple sclerosis	5.21e-05	0.00116	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	5.2e-05	0.00116	CcSEcCtD
Vidarabine—Dizziness—Prednisolone—multiple sclerosis	5.2e-05	0.00116	CcSEcCtD
Vidarabine—Asthenia—Triamcinolone—multiple sclerosis	5.18e-05	0.00116	CcSEcCtD
Vidarabine—Asthenia—Methylprednisolone—multiple sclerosis	5.17e-05	0.00115	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—multiple sclerosis	5.13e-05	0.00114	CcSEcCtD
Vidarabine—Cough—Methotrexate—multiple sclerosis	5.1e-05	0.00114	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—multiple sclerosis	5.07e-05	0.00113	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—multiple sclerosis	4.98e-05	0.00111	CcSEcCtD
Vidarabine—Rash—Prednisolone—multiple sclerosis	4.95e-05	0.00111	CcSEcCtD
Vidarabine—Dermatitis—Prednisolone—multiple sclerosis	4.95e-05	0.0011	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—CNR1—multiple sclerosis	4.93e-05	0.0129	CbGpPWpGaD
Vidarabine—Headache—Prednisolone—multiple sclerosis	4.92e-05	0.0011	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—multiple sclerosis	4.92e-05	0.0011	CcSEcCtD
Vidarabine—Dizziness—Triamcinolone—multiple sclerosis	4.78e-05	0.00107	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—multiple sclerosis	4.77e-05	0.00106	CcSEcCtD
Vidarabine—Dizziness—Methylprednisolone—multiple sclerosis	4.77e-05	0.00106	CcSEcCtD
Vidarabine—Asthenia—Dexamethasone—multiple sclerosis	4.7e-05	0.00105	CcSEcCtD
Vidarabine—Asthenia—Betamethasone—multiple sclerosis	4.7e-05	0.00105	CcSEcCtD
Vidarabine—Nausea—Prednisolone—multiple sclerosis	4.67e-05	0.00104	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—multiple sclerosis	4.61e-05	0.00103	CcSEcCtD
Vidarabine—ADORA2A—Monoamine Transport—IL1B—multiple sclerosis	4.61e-05	0.0121	CbGpPWpGaD
Vidarabine—Vomiting—Triamcinolone—multiple sclerosis	4.59e-05	0.00103	CcSEcCtD
Vidarabine—Vomiting—Methylprednisolone—multiple sclerosis	4.58e-05	0.00102	CcSEcCtD
Vidarabine—Rash—Triamcinolone—multiple sclerosis	4.56e-05	0.00102	CcSEcCtD
Vidarabine—Dermatitis—Triamcinolone—multiple sclerosis	4.55e-05	0.00102	CcSEcCtD
Vidarabine—Rash—Methylprednisolone—multiple sclerosis	4.55e-05	0.00101	CcSEcCtD
Vidarabine—Dermatitis—Methylprednisolone—multiple sclerosis	4.54e-05	0.00101	CcSEcCtD
Vidarabine—Urticaria—Prednisone—multiple sclerosis	4.54e-05	0.00101	CcSEcCtD
Vidarabine—Headache—Triamcinolone—multiple sclerosis	4.53e-05	0.00101	CcSEcCtD
Vidarabine—Headache—Methylprednisolone—multiple sclerosis	4.52e-05	0.00101	CcSEcCtD
Vidarabine—ADK—Metabolism—SRM—multiple sclerosis	4.47e-05	0.0117	CbGpPWpGaD
Vidarabine—Hypotension—Methotrexate—multiple sclerosis	4.46e-05	0.000995	CcSEcCtD
Vidarabine—ADORA2A—G alpha (s) signalling events—PTGER4—multiple sclerosis	4.44e-05	0.0116	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	4.35e-05	0.00097	CcSEcCtD
Vidarabine—Dizziness—Dexamethasone—multiple sclerosis	4.34e-05	0.000967	CcSEcCtD
Vidarabine—Dizziness—Betamethasone—multiple sclerosis	4.34e-05	0.000967	CcSEcCtD
Vidarabine—Nausea—Triamcinolone—multiple sclerosis	4.29e-05	0.000958	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—multiple sclerosis	4.28e-05	0.000956	CcSEcCtD
Vidarabine—Nausea—Methylprednisolone—multiple sclerosis	4.28e-05	0.000955	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—multiple sclerosis	4.25e-05	0.000949	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—multiple sclerosis	4.24e-05	0.000946	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisone—multiple sclerosis	4.21e-05	0.000939	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	4.19e-05	0.011	CbGpPWpGaD
Vidarabine—Vomiting—Betamethasone—multiple sclerosis	4.17e-05	0.00093	CcSEcCtD
Vidarabine—Vomiting—Dexamethasone—multiple sclerosis	4.17e-05	0.00093	CcSEcCtD
Vidarabine—Rash—Dexamethasone—multiple sclerosis	4.13e-05	0.000922	CcSEcCtD
Vidarabine—Rash—Betamethasone—multiple sclerosis	4.13e-05	0.000922	CcSEcCtD
Vidarabine—Dermatitis—Dexamethasone—multiple sclerosis	4.13e-05	0.000921	CcSEcCtD
Vidarabine—Dermatitis—Betamethasone—multiple sclerosis	4.13e-05	0.000921	CcSEcCtD
Vidarabine—Headache—Betamethasone—multiple sclerosis	4.11e-05	0.000916	CcSEcCtD
Vidarabine—Headache—Dexamethasone—multiple sclerosis	4.11e-05	0.000916	CcSEcCtD
Vidarabine—Asthenia—Prednisone—multiple sclerosis	4.1e-05	0.000914	CcSEcCtD
Vidarabine—Pain—Methotrexate—multiple sclerosis	4.08e-05	0.00091	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—SLC30A7—multiple sclerosis	4.06e-05	0.0106	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CD4—multiple sclerosis	4.02e-05	0.0105	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	3.94e-05	0.0103	CbGpPWpGaD
Vidarabine—Nausea—Dexamethasone—multiple sclerosis	3.89e-05	0.000869	CcSEcCtD
Vidarabine—Nausea—Betamethasone—multiple sclerosis	3.89e-05	0.000869	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—multiple sclerosis	3.79e-05	0.000846	CcSEcCtD
Vidarabine—Dizziness—Prednisone—multiple sclerosis	3.78e-05	0.000842	CcSEcCtD
Vidarabine—Vomiting—Prednisone—multiple sclerosis	3.63e-05	0.00081	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	3.6e-05	0.00943	CbGpPWpGaD
Vidarabine—Rash—Prednisone—multiple sclerosis	3.6e-05	0.000803	CcSEcCtD
Vidarabine—Dermatitis—Prednisone—multiple sclerosis	3.6e-05	0.000802	CcSEcCtD
Vidarabine—Headache—Prednisone—multiple sclerosis	3.58e-05	0.000798	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—multiple sclerosis	3.52e-05	0.000784	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Other—CCR5—multiple sclerosis	3.45e-05	0.00901	CbGpPWpGaD
Vidarabine—Asthenia—Methotrexate—multiple sclerosis	3.42e-05	0.000764	CcSEcCtD
Vidarabine—Nausea—Prednisone—multiple sclerosis	3.39e-05	0.000757	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	3.38e-05	0.00884	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TNF—multiple sclerosis	3.35e-05	0.00875	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—PABPC1—multiple sclerosis	3.29e-05	0.0086	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—S1PR1—multiple sclerosis	3.19e-05	0.00835	CbGpPWpGaD
Vidarabine—Dizziness—Methotrexate—multiple sclerosis	3.16e-05	0.000704	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—FAS—multiple sclerosis	3.15e-05	0.00825	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP27B1—multiple sclerosis	3.15e-05	0.00824	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP24A1—multiple sclerosis	3.15e-05	0.00824	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	3.09e-05	0.00808	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	3.09e-05	0.00808	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SRM—multiple sclerosis	3.04e-05	0.00795	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—MYC—multiple sclerosis	3.03e-05	0.00794	CbGpPWpGaD
Vidarabine—Vomiting—Methotrexate—multiple sclerosis	3.03e-05	0.000677	CcSEcCtD
Vidarabine—Rash—Methotrexate—multiple sclerosis	3.01e-05	0.000671	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—multiple sclerosis	3.01e-05	0.000671	CcSEcCtD
Vidarabine—Headache—Methotrexate—multiple sclerosis	2.99e-05	0.000667	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—RPL5—multiple sclerosis	2.96e-05	0.00775	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—MYC—multiple sclerosis	2.89e-05	0.00756	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GPC5—multiple sclerosis	2.88e-05	0.00754	CbGpPWpGaD
Vidarabine—Nausea—Methotrexate—multiple sclerosis	2.83e-05	0.000632	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CD28—multiple sclerosis	2.83e-05	0.00741	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—GPR65—multiple sclerosis	2.57e-05	0.00673	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	2.47e-05	0.00647	CbGpPWpGaD
Vidarabine—ADK—Metabolism—RRM1—multiple sclerosis	2.39e-05	0.00625	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	2.39e-05	0.00625	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCR1—multiple sclerosis	2.35e-05	0.00615	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL13—multiple sclerosis	2.35e-05	0.00615	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	2.32e-05	0.00608	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	2.2e-05	0.00576	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CD28—multiple sclerosis	2.18e-05	0.0057	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—BCHE—multiple sclerosis	2.17e-05	0.00568	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	2.14e-05	0.00561	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP27B1—multiple sclerosis	2.14e-05	0.0056	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP24A1—multiple sclerosis	2.14e-05	0.0056	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	2.12e-05	0.00554	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—POMC—multiple sclerosis	2.1e-05	0.0055	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	2.05e-05	0.00535	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CD86—multiple sclerosis	2.02e-05	0.00529	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	1.99e-05	0.00521	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPC5—multiple sclerosis	1.96e-05	0.00513	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	1.84e-05	0.00481	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—FAS—multiple sclerosis	1.81e-05	0.00474	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—S1PR1—multiple sclerosis	1.8e-05	0.00472	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCL3—multiple sclerosis	1.68e-05	0.00438	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	1.65e-05	0.00433	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—S1PR1—multiple sclerosis	1.64e-05	0.00428	CbGpPWpGaD
Vidarabine—ADA—Metabolism—RRM1—multiple sclerosis	1.62e-05	0.00425	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—PTGER4—multiple sclerosis	1.61e-05	0.00422	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCR3—multiple sclerosis	1.56e-05	0.00408	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CD86—multiple sclerosis	1.55e-05	0.00407	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—RGS1—multiple sclerosis	1.53e-05	0.00401	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCR2—multiple sclerosis	1.52e-05	0.00397	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	1.5e-05	0.00392	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CD80—multiple sclerosis	1.47e-05	0.00386	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GPR65—multiple sclerosis	1.45e-05	0.0038	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	1.42e-05	0.00372	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CNR1—multiple sclerosis	1.4e-05	0.00366	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RGS1—multiple sclerosis	1.39e-05	0.00364	CbGpPWpGaD
Vidarabine—ADK—Metabolism—BCHE—multiple sclerosis	1.37e-05	0.00359	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCR1—multiple sclerosis	1.33e-05	0.00348	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL13—multiple sclerosis	1.33e-05	0.00348	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GPR65—multiple sclerosis	1.32e-05	0.00345	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	1.28e-05	0.00336	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LINGO1—multiple sclerosis	1.28e-05	0.00334	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL10—multiple sclerosis	1.26e-05	0.00329	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—TYK2—multiple sclerosis	1.24e-05	0.00326	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL13—multiple sclerosis	1.21e-05	0.00316	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCR1—multiple sclerosis	1.21e-05	0.00316	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CD80—multiple sclerosis	1.13e-05	0.00297	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—POMC—multiple sclerosis	1.12e-05	0.00293	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TAGAP—multiple sclerosis	1.11e-05	0.00289	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CCL2—multiple sclerosis	1.1e-05	0.00287	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCL5—multiple sclerosis	1.08e-05	0.00284	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—IL6—multiple sclerosis	1.08e-05	0.00283	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	1e-05	0.00262	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	9.81e-06	0.00257	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCR5—multiple sclerosis	9.77e-06	0.00256	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—S1PR1—multiple sclerosis	9.67e-06	0.00253	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—TYK2—multiple sclerosis	9.57e-06	0.0025	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GPC5—multiple sclerosis	9.41e-06	0.00246	CbGpPWpGaD
Vidarabine—ADA—Metabolism—BCHE—multiple sclerosis	9.32e-06	0.00244	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTGER4—multiple sclerosis	9.12e-06	0.00239	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCR3—multiple sclerosis	8.8e-06	0.0023	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—multiple sclerosis	8.71e-06	0.00228	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCL3—multiple sclerosis	8.6e-06	0.00225	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCR2—multiple sclerosis	8.56e-06	0.00224	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTGER4—multiple sclerosis	8.28e-06	0.00217	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APOE—multiple sclerosis	8.25e-06	0.00216	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RGS1—multiple sclerosis	8.22e-06	0.00215	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCR3—multiple sclerosis	8e-06	0.00209	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK1—multiple sclerosis	7.92e-06	0.00207	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CNR1—multiple sclerosis	7.9e-06	0.00207	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GPR65—multiple sclerosis	7.8e-06	0.00204	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCR2—multiple sclerosis	7.78e-06	0.00203	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—POMC—multiple sclerosis	7.63e-06	0.002	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCL2—multiple sclerosis	7.47e-06	0.00195	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CNR1—multiple sclerosis	7.18e-06	0.00188	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL13—multiple sclerosis	7.13e-06	0.00187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCR1—multiple sclerosis	7.13e-06	0.00187	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	7.12e-06	0.00186	CbGpPWpGaD
Vidarabine—ADK—Metabolism—POMC—multiple sclerosis	7.09e-06	0.00185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—multiple sclerosis	6.7e-06	0.00175	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL10—multiple sclerosis	6.46e-06	0.00169	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—multiple sclerosis	6.46e-06	0.00169	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—multiple sclerosis	6.21e-06	0.00162	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCL5—multiple sclerosis	6.13e-06	0.0016	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAPK1—multiple sclerosis	6.09e-06	0.00159	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	6.09e-06	0.00159	CbGpPWpGaD
Vidarabine—ADA—Metabolism—APOE—multiple sclerosis	5.61e-06	0.00147	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCL5—multiple sclerosis	5.56e-06	0.00146	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCR5—multiple sclerosis	5.52e-06	0.00144	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	5.44e-06	0.00142	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL3—multiple sclerosis	5.08e-06	0.00133	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCR5—multiple sclerosis	5.01e-06	0.00131	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2RA—multiple sclerosis	4.94e-06	0.00129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTGER4—multiple sclerosis	4.89e-06	0.00128	CbGpPWpGaD
Vidarabine—ADA—Metabolism—POMC—multiple sclerosis	4.82e-06	0.00126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PGR—multiple sclerosis	4.82e-06	0.00126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCR3—multiple sclerosis	4.72e-06	0.00124	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—multiple sclerosis	4.68e-06	0.00122	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CD28—multiple sclerosis	4.68e-06	0.00122	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCR2—multiple sclerosis	4.59e-06	0.0012	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—multiple sclerosis	4.39e-06	0.00115	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—POMC—multiple sclerosis	4.31e-06	0.00113	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CNR1—multiple sclerosis	4.24e-06	0.00111	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—POMC—multiple sclerosis	3.92e-06	0.00102	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCL2—multiple sclerosis	3.83e-06	0.001	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL10—multiple sclerosis	3.82e-06	0.000999	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—TYK2—multiple sclerosis	3.48e-06	0.000911	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CD86—multiple sclerosis	3.34e-06	0.000873	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL5—multiple sclerosis	3.29e-06	0.00086	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—multiple sclerosis	3.19e-06	0.000834	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SPP1—multiple sclerosis	3.04e-06	0.000796	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCR5—multiple sclerosis	2.96e-06	0.000775	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2RA—multiple sclerosis	2.92e-06	0.000763	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—multiple sclerosis	2.9e-06	0.000758	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APOE—multiple sclerosis	2.69e-06	0.000705	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CD80—multiple sclerosis	2.44e-06	0.000637	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—POMC—multiple sclerosis	2.31e-06	0.000605	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL2—multiple sclerosis	2.26e-06	0.000592	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAPK1—multiple sclerosis	2.22e-06	0.00058	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TYK2—multiple sclerosis	2.06e-06	0.000538	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—multiple sclerosis	1.71e-06	0.000448	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—multiple sclerosis	1.7e-06	0.000445	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—multiple sclerosis	1.62e-06	0.000424	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—multiple sclerosis	1.44e-06	0.000377	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—multiple sclerosis	1.34e-06	0.00035	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—multiple sclerosis	1.33e-06	0.000349	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAPK1—multiple sclerosis	1.31e-06	0.000342	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—multiple sclerosis	1.01e-06	0.000263	CbGpPWpGaD
